Gene and modified cell therapies (for example, chimeric antigen receptor T-cell therapies) in early to late clinical development are showing significant promise to treat and potentially cure many diseases. A few of these...
Scale-down models need to exactly mimic the critical process parameter to be studied and optimized. Considering this, there are probably still some gaps with regards to scale-down solutions in upstream and downstream process development, particularly for continuous applications. The most accurate models use miniature bioreactors because these do a good job of replicating results seen in benchtop instruments.
Thermo Fisher Scientific has agreed to acquire Brammer Bio for $1.7 billion cash, the companies said, in a deal designed to increase the buyer’s presence in gene therapy with the viral vector contract development...
Amicus Therapeutics will address clinical and commercial supply needs for its intrathecal AAV Batten disease gene therapy programs by partnering with Thermo Fisher Scientific’s recently-acquired Brammer Bio.
908 Devices benchtop analyzer allows biopharma researchers to accelerate process-development cycles and maximize their bioreactor utilization by running media analysis at-line, anytime.
Firm will now be able to use Esetec, which comprises a specific E. coli strain developed by Wacker, to produce antigen material.
Part of bacteria’s genome is removed, with the goal of enhancing its use in the production of new therapeutics.
Lonza has further expanded its growing presence in mammalian manufacturing by acquiring a clinical-stage site in Hayward, CA, from Shire for an undisclosed price
Please wait while you are redirected to the right page...